Trump’s Aggressive Advocacy of Malaria Drug for Treating Coronavirus Divides Medical Community

Spread the love

Another investor in both Sanofi and Mylan, another pharmaceutical firm, is Invesco, the fund previously run by Wilbur Ross, the commerce secretary. Mr. Ross said in a statement Monday that he “was not aware that Invesco has any investments in companies producing” the drug, “nor do I have any involvement in the decision to explore this as a treatment.”

As of last year, Mr. Trump reported that his three family trusts each had investments in a Dodge & Cox mutual fund, whose largest holding was in Sanofi.

Several generic drugmakers are gearing up to produce hydroxychloroquine pills, including Amneal Pharmaceuticals, whose co-founder Chirag Patel is a member of Trump National Golf Course Bedminster in New Jersey and has golfed with Mr. Trump at least twice since he became president, according to a person who saw them.

Mr. Patel, whose company is based in Bridgewater, N.J., did not respond to a request for comment. Amneal announced last month that it would increase production of the drug and donate millions of pills to New York and other states. Other generic drugmakers are ramping up production, including Mylan and Teva Pharmaceutical Industries.

Roberto Mignone, a Teva board member, reached out to the team of Jared Kushner, the president’s son-in-law and senior adviser, through Nitin Saigal, who used to work for Mr. Mignone and is a friend of Mr. Kushner’s, according to people informed about the discussions.

Mr. Kushner’s team referred him to the White House task force and Mr. Mignone asked for help getting India to ease export restrictions, which have since been relaxed, allowing Teva to bring more pills into the United States. Mr. Mignone, who is also a vice chairman of NYU Langone Health, which is running a clinical study of hydroxychloroquine, confirmed on Monday that he has spoken with the administration about getting more medicine into the country.

Dr. Daniel H. Sterman, the critical care director at NYU Langone Health, said doctors there are using hydroxychloroquine, but data about its effectiveness remained “weak and unsubstantiated” pending the study. “We do not know whether our patients are benefiting from hydroxychloroquine treatment at the present time,” he said.